The Everyday Brief — home

The Everyday
Brief

Everyday life, clearly explained

Will Adding Thymosin Alpha-1 to Entecavir Lower Liver Cancer Risk?

Your uncle has hepatitis B with early cirrhosis and takes an antiviral pill, entecavir, every day. At a family dinner someone mentions thymosin alpha-1, an immune peptide sold abroad as Zadaxin and online as a research product, and asks whether adding it would lower his chance of liver cancer. That is a fair question, and it has been tested in a large trial.

The biggest randomized study, with 690 people with hepatitis B cirrhosis already on entecavir, found that a year of added thymosin alpha-1 did not reduce liver failure, liver cancer or death compared with entecavir alone over about three years. Smaller trials saw early bumps in lab markers that faded within a year. A new Cochrane review calls the overall evidence very uncertain.

The large entecavir trial

Researchers at hospitals across China, led by a team at Beijing Friendship Hospital, enrolled adults with compensated cirrhosis, meaning the liver was scarred but still coping. After six months on entecavir, 351 people also received thymosin alpha-1 for 52 weeks and 339 stayed on entecavir alone. Everyone continued the antiviral afterward. The study was open-label, so patients and doctors knew who got the add-on.

Over a median of about 38 months, the combined rate of liver decompensation, liver cancer or death was similar in the two groups. During the year of combined treatment, liver cancer appeared in 1.7 percent of the add-on group and 2.1 percent of the entecavir-only group, a small gap the authors described only as a tendency. Virus levels, antibody changes and liver enzyme results were also similar by week 104. Both approaches were well tolerated.

Smaller trials and the 2026 Cochrane review

A Korean pilot trial published in 2008 tested the peptide with an older antiviral, lamivudine, in 67 people with active, e antigen-positive hepatitis B. At 24 weeks, more people on the combination had cleared that antigen, about 26 percent versus 6 percent. By 52 weeks the gap was no longer statistically clear, and viral breakthrough was not lower with the add-on (35 percent versus 21 percent, also not significant).

A 2020 meta-analysis of seven randomized trials in 1,144 people with hepatitis B cirrhosis, all in mainland China, found the same pattern. Adding thymosin alpha-1 to entecavir raised some response measures 24 weeks after treatment, but by 48 to 52 weeks the difference was not significant. The authors asked for larger trials outside China.

The Cochrane Hepato-Biliary Group updated its review in September 2026, pooling 10 randomized trials with 1,349 adults. In three trials with 907 people, deaths were lower with thymosin alpha-1, but the reviewers rated that evidence very low certainty because of bias risks, small numbers and wide uncertainty. The effect on hepatitis B complications was very uncertain, and they found no ongoing trials. They concluded they could not be sure the peptide changes deaths or complications.

Questions worth asking the liver clinic

For someone in your uncle’s position, the practical message is that the antiviral is the treatment with the solid track record, and staying on it matters more than any add-on. Ask the hepatology team how often liver cancer screening should happen with cirrhosis, what his recent virus and liver numbers mean, and whether any add-on would be given inside a clinical trial. Thymosin alpha-1 is not approved for hepatitis B in the United States, and research-catalog vials labeled for laboratory use are not the products used in these hospital studies. Not medical advice.

Sources

Related reading

By The Everyday Brief. AI-assisted drafting with automated source and editorial checks. Sources fetched 2026-10-24 PT. Not medical advice.

← Browse all stories